Background and Objectives: Cutaneous pigmentary disorders are both more common and more difficult to treat in patients with skin color given the higher melanin content in the epidermis. Although Q-switched lasers are widely considered to be the standard treatment for both epidermal and dermal pigmentary conditions, a very high risk of post-inflammatory hyperpigmentation (PIH) of up to 25% is seen in patients with skin of color. Recently, the novel picosecond laser with pulse durations operating at sub-nanosecond domains has been shown to be effective in tattoo removal and in the treatment of acne scars. The objective of this study is to examine the safety and efficacy of the dual wavelength picosecond laser for the treatment of benign pigmented skin lesions in Asian patients. Methods: Twelve subjects with benign pigmentary disorders and Fitzpatrick skin types III to IV were recruited in a prospective clinical study to examine the safety and efficacy of the dual wavelength picosecond laser. Patients were treated at approximately 2-6 week intervals depending of the type of lesion. The primary efficacy endpoint is the global percent of clearance which was evaluated by blinded observers using post treatment photographs compared to baseline photographs. Safety was evaluated before and after each laser treatment and patients were asked to rate the level of pain according to the Visual Analog Scale after each treatment session. Patient satisfaction was assessed at the completion of treatment with questionnaires. All patients were followed up at 4, 8, and 12 weeks after the last treatment session. Results: The pigmentary conditions treated included melasma, freckles, lentiginies, caf e au lait macules, and Hori's macules. Three months after treatment, 53.8% of all pigments achieved excellent response (75-94% lightening,) 30.8% of pigments achieved good response (50-74% lightening,) and 7.7% of pigments achieved both fair (25-49% lightening) and poor responses (0-24% lightening), respectively. The average number of treatment sessions required to reach at least 50% clearance was 4.5 for melasma, 1 for freckles, 1.5 for lentigines and 1 for caf e au lait. The patient with Hori's macules did not reach 50% clearance after a total of six treatments. Sixty three percent of patients reported satisfaction in the subjective assessment, while 27.3% were neutral and 9.1% were very dissatisfied. The post inflammatory hyperpigmentation rate was 4.8% and 6.5% of subjects developed blistering as a side effect of treatment. Conclusion: The dual wavelength picosecond laser is a safe and effective treatment of benign pigmentary conditions in patients with skin of color. In particular, superior clinical efficacy is demonstrated for treatment of freckles and lentigines with a low risk of PIH. Lasers Surg. Med. 51:14-22, 2019.
INTRODUCTION
Laser technologies have been extensively used to treat benign epidermal and dermal pigmented lesions over the past 20 years since Anderson et al first described the use of Q-switched (QS) Nd: YAG laser to treat cutaneous pigmentation [1] . Since then, various laser modalities including the QS 532 nm neodymium-yttrium-aluminiumgarnet (Nd:YAG) laser, QS alexandrite laser (755 nm), QS ruby laser (694 nm), intense pulsed light (IPL) source, and long pulsed 532-nm Nd:YAG laser have been shown to be effective in treating benign pigmented lesions. However, studies have shown that the use of Q-switched lasers to treat pigmented lesions in Asians were associated with a high risk of post inflammatory hyperpigmentation of up to 25% [2] [3] [4] .
Recently, the picosecond Nd:YAG laser with pulse durations operating at the sub-nanosecond range as short as 450 picoseconds (ps) have become commercially available. Picosecond lasers have the advantage of greater photomechanical effect and higher peak temperature generation with less unwanted heat diffusion into neighboring structures. Lower fluences of energy can be used for effective treatment by utilizing picosecond pulses [5, 6] . This improves the side effect profile by reducing the risk of epidermal injury and dyspigmentation [7] [8] . Ross et al. [9] were the first to demonstrate the use of picosecond laser to remove tattoos.
To date, there has been little data on the use of the dualwavelength picosecond laser in treatment of benign pigmented lesions in Asian. The objective of this study is to demonstrate the safety and efficacy of the dualwavelength picosecond laser for the treatment of benign pigmented lesions, including solar lentigines, freckles, caf e au lait macules, melasma, and Hori's Macules.
MATERIALS AND METHODS
This is a prospective clinical trial which was conducted in accordance with the Declaration of Helsinki, US Code of Federal Regulations and the International Conference on Harmonization (ICH.) The study had received Chesapeake Institutional Review Board Approval. Twelve subjects with benign pigmented lesions were recruited into the study. All study subjects were female aged 21-57 years with Fitzpatrick skin type III to IV. Patients were recruited after informed consent was obtained and the following exclusion criteria were absent: photosensitivity or taking drugs known to induce photosensitivity, active sun tan, active localized or systemic infection, history of squamous cell carcinoma or melanoma, history of keloid scarring, allergy to local anaesthetics, use of oral isotretinoin within 12 months of initial treatment or plan to use during course of study, had a laser procedure, peel or used lightening creams in the treatment area within the past 6 months. Patients who were either pregnant, lactating or had a history of immunosuppression/immune deficiency disorders were also excluded. The maximum size of each lesion treated in the study is 10 Â 10 cm and subjects with pigmented lesions that were not considered acceptable or safe to treat by the dermatologist were not included in the study. All pigmented lesions will be considered independent of body location.
Intervention
The investigational device is a dual wavelength laser system developed for treatment of pigmented lesions and for tattoo removal by Candela Corporation, Wayland, MA. The base unit is a GentleMax Pro laser system modified to emit light at wavelengths of 532 and 1064 nm and deliver pulse energy up to 400 mJ, and pulse duration of 450 ps. (Picoway 1 Syneron Candela Corp, Wayland, MA). Treatment sessions involving the pigmented lesion will be repeated at approximately 2-6 week intervals (þ/À2 weeks) depending on the type of lesion. Melasma can be treated at 2-4 weekly interval, freckle and lentigo or Nevus of Ota or Nevus of Ito can be treated 4-6 weeks between treatments. Epidermal lesions such as freckles may require as few as three treatments while dermal lesions may require up to nine treatments depending on the severity and response of the lesion. More than one lesion may be treated per subject and the entire lesional area will be treated. The treatment wavelength will be selected by the treating physician based on the lesion and the subject's skin phototype. Prior to treatment, a topical anesthetic (EMLA, or LMX-4 cream, Ferndale, Laboratories, Ferndale, MI) will be applied to the treatment area 40 minutes before treatment. Eye protection will be worn during the procedure. Treatment parameters will be guided by patient skin type and achievement of clinical end point, namely epidermal whitening, during the initial test spot. Test spots of increasing fluence will be used to achieve the desired endpoint. Immediately following treatment, a lubricant (Aquaphor healing ointment or Vaseline) will be applied to the treatment area under occlusion and the subject will be advised to use sun protection and avoid sun exposure for the entire duration of the study.
The subject will be asked to return to the clinic for follow up evaluation at 4, 8, and 12 weeks after the last treatment session. During the follow up visits, the treatment area will be photographed and the presence and severity of side effects will be assessed. The four patients with melasma were treated during the summer months and followed up during the winter and spring season.
All side effects will be noted immediately after laser treatment and before each subsequent laser treatment session. Photographs of the treated area will be taken before treatments begin, immediately after each laser Treatment sessions involving the pigmented lesion will be repeated at roughly 2-6 week (þ/À 2 week) intervals. Epidermal lesions may be treated as soon as 2 weeks. Dermal lesions may be treated up to 6 weeks.
treatment, and at the follow up evaluation visit. After all subjects have completed treatment, each subject's pre-and post-treatment photographs will be evaluated by blinded observers for clearance and side effects. If the lesion is not cleared after all study visits have been completed, there are different treatment options available. Study doctor may propose at his discretion additional treatment using other FDA cleared devices. All such treatments are not covered by this study and will be performed at the subject's expense.
Evaluation of Efficacy
The primary efficacy endpoint for this study is global percent of clearance which will be assessed after two treatments for all lesion types, except Melasma, which will be assessed post four treatments, or at the 3 month follow up visit. The clearance will be evaluated by blinded observers using post treatment photographs compared to baseline photographs. Global percent of pigment clearance is evaluated over the entire treatment area. Clearance will be assessed using a scale from 1 to 5; Grade 5, complete response (!95% lightening,) Grade 4, excellent response (75-94% lightening,) Grade 3, good response (50-74% lightening,) Grade 2, fair response (25-49% lightening,) and Grade 1, poor response (0-24% lightening).
Overall physician satisfaction was also recorded by the investigator where she rated whether she was very satisfied, somewhat satisfied, neutral, somewhat dissatisfied, or very dissatisfied with the treatment at each visit.
Subject satisfaction will be evaluated after completion of all treatments and follow up visit and will be assessed with questionnaires. In the subjective assessment, patients will be asked to rate the level of pain after each treatment using the Numerical Visual Analogue Scale from no pain (O) to worst possible pain (10) . The pain assessment scores obtained immediately post treatment will be tabulated and the mean value off overall treatment will be calculated.
Evaluation of Safety
Safety will be evaluated immediately after and before each subsequent laser treatment and will be based on the incidence and severity of side effects caused by laser treatments. Expected side effects include post treatment purpura, pinpoint bleeding, edema, erythema, hyperpigmentation and hypopigmentation, blistering, crusting, and scarring. These will be assessed immediately after each treatment using a scale form 0 (absent) to 3 (severe). The incidence and mean severity scores for each potential side effect from each visit will be tabulated.
Photographic Documentation
The pigmented lesions will be photographed before and after each treatment session and at each follow up evaluation visit using a Canfield VISIA-CR system (Canfield Scientific Inc, Parsippany, NJ). Standardized photography in terms of distance and lighting will be used each time.
Statistical Analysis
Mean clearance will be calculated and tested for significance using ANOVA. The rate of pigmented lesion clearance will also be investigated by determining the percentage of lesions having grades 1 and 2 clearance over all treatments. In addition, the mean number of treatments needed to achieve 50% clearance will be calculated globally independent of lesion type and color and individually based on the lesion type.
RESULTS

Patient Demographics
A total of twelve patients were enrolled into the study, however one patient defaulted subsequent follow up, therefore data from 11 patients were analyzed. All patients were female, the mean age being 47.3 þ/À7.6 years (range: 37-57) 27.3% of the patients had Fitzpatrick skin type III, while the rest (72.7%) had Fitzpatrick skin type IV. A total of 13 pigments were treated in total, the patient demographics, distribution of pigment types and the number of treatment sessions needed are shown in Table 1 . The laser parameters used for treatment of individual lesions are summarized in Table 2 . The procedure was well tolerated by patients and on the 10-point visual analog scale, pain was rated at an average of 3.4þ/À 2.3 out of 10.
Clinical Efficacy
The overall clinical response based on objective assessment is highlighted Graph 1. A total of 12 out of the 13 pigments were included in the objective assessment as the patient with Hori's macules did not achieve 50% clearance after a total of six treatments and was thus excluded from the objective assessment.
With the exception of Hori's Macules, all subjects obtained clinical improvement with best results seen in treatment of lentigines (Fig. 1) , where 100% of lesions achieved excellent response (75-94% lightening) after two treatment sessions and in treatment of freckles (Figs. 2  and 3 ). The response of each individual pigment to treatment is summarized in Table 3 . The subject satisfaction ratings are shown in Graph 2.
At 1 month follow up, the investigator was very satisfied at 61.5% of the time. It subsequently decreased to 50% at 2 months follow up and 38.1% at 3 months follow up (Fig. 4) .
Safety Analysis
Adverse effects were assessed after each treatment session and were mostly mild and transient. The most common adverse effect was erythema (mild to moderate) and edema (mild to moderate). The adverse effect is summarized in Table 4 .
Reported adverse events included blistering which occurred in two cases total four treatment and post inflammatory hyperpigmentation which appeared in three cases (Fig. 5) . None of the patients received any additional treatment for PIH induced during treatment.
DISCUSSION
Laser treatment of pigmented skin lesions in patients with skin of color remains challenging, despite the higher occurrence of pigmented skin lesions in this group of patients. The highly melanised epidermis [10] contains melanosomes which are larger and nonaggregated [11, 12] . The higher melanin content can absorb laser energy and induce thermal injury to neighboring structures thus resulting in increased risks of unwanted side effects such as post inflammatory hyperpigmentation and scarring [13] . The melanin also acts as a competitive chromophore to absorb laser energy intended for treatment targets therefore reducing treatment efficacy. In treating patients with skin of color, unique laser parameters with longer wavelengths, lower treatment fluences and the use of epidermal cooling devices have been shown to reduce the risk of complications.
The treatment of pigmented skin lesions by Q-switched lasers (ruby, alexandrite, and Nd:YAG), fractional photothermolysis and other non-ablative laser therapies have been shown to be effective [14] . In particular, the Q switched lasers which deliver pulse durations in the nanosecond domains have been widely considered as the laser of choice to treat both epidermal and dermal pigmentary disorders. Conforming to the theory of selective thermolysis, photothermal effects are maximized when chromophores receive energy at wavelengths operating at durations less than or equal to their thermal relaxation times. The short pulse durations of Q switched lasers allow for optimal, targeted photothermal damage to melasomes which has a thermal relaxation time of between 50 and 250 nanoseconds [15] . The Picosecond Laser is a new laser technology that utilizes even shorter bursts of energy in the picosecond range to effectively deliver targeted photothermal and photomechanical effects. The strong photomechanical effect fragments pigment while using lower fluences of energy [16, 17] thus reducing the risk of epidermal injury and post inflammatory hyperpigmentation. Several studies have already shown the effectiveness of the 755-nm Picosecond laser in tattoo removal [9, [16] [17] [18] and in the treatment of benign pigmented lesions [14, 19] . To the best of our knowledge, this is the first study to examine the safety and efficacy of the dual wavelength picosecond laser in the treatment of benign pigmentary disorders in Asian.
Our study has shown the dual wavelength picosecond laser is an effective and safe device to treat both epidermal and dermal pigmented lesions and the results are comparable to that of the 755 nm Picosecond laser and Q switched lasers. In our series, comparable efficacy was demonstrated in the treatment of Caf e Au Lait macules and lentigines compared with a retrospective case series using the 755 nm picosecond laser [17] . All of our patients with lentigines achieved excellent response after two treatments, compared with only fair response using the 755 nm Picosecond laser. For patients with caf e au lait macules 50% achieved excellent and 50% achieved good responses in our series (Fig. 6 ) compared with good response in 40% and fair response in 60% using the 755 nm Picosecond laser. The clinical efficacy is also comparable to that of the Q switched laser [20, 21] . The treatment of Caf e Au Lait macules is known to be challenging given there is a follicular melanocytic component which cannot be targeted by the QS lasers. The results shown in our series is comparable to that of the QS 755-nm Alexandrite laser where a retrospective study showed that after an average of 3.2 treatments, good to excellent responses occurred in 54.1%, poor response in 16.7%, and recurrence occurred in 10.4% of all patients Graph 2. Subjective satisfaction. [22]. Another study using QS 694 nm ruby laser and QS 532 nm Nd:YAG laser concurred similar variable results [23] . Similar to the 755 nm Picosecond laser which produced fair responses in clearing after eight sessions for treatment of Hori's Macules, the patient with Hori's Macules in our case series only achieved poor response despite six treatment sessions. One possible explanation is that there was only one single patient recruited in both studies and further, large scale studies are needed to elucidate the clinical efficacy.
Overall, our study has demonstrated that the dual wavelength picosecond laser is a safe device with high patient tolerability. The rate of post-inflammatory hyperpigmentation in our case series in 4.8% compared with a much higher rate of PIH reaching 25% induced by Q switched lasers. The lower rate of PIH induced by picosecond lasers can be explained by a much more targeted photomechanical and lesser photothermal effects. QS lasers destroy melanin through both photomechanical and photothermal effects when short bursts (nanoseconds) of wavelength-specific energy are delivered to the skin. Excessive photothermal injury can diffuse to neighboring structures and since the picosecond laser has even shorter pulse durations than the thermal relaxation time of melanosomes, the photothermal energy can be better confined to minimize collateral damage. In addition, the picosecond laser utilizes intense photomechanical impact to fragment pigments while using much lower laser energy levels compared with QS lasers. The unwanted photomechanical effects induced by QS lasers induce damage to the surrounding oxyhaemoglobin to cause inflammation to the superficial blood vessels and change in melanocyte activity which results in PIH. The mean VAS pain score of 3.4 is comparable to values reported using the 755 nm picosecond laser and QS lasers of 3.0 and 2.46, respectively [14] .
In summary, we have demonstrated that the novel dual wavelength picosecond laser is both safe and effective in treating epidermal and dermal pigmentary disorders in patients with skin of color. In particular, the dual wavelength picosecond laser has shown superior clinical efficacy in the treatment of freckles, lentigines, and caf e au lait macules, requiring fewer treatment sessions compared with the QS counterparts. The overall safety profile is favorable, with good patient tolerability and a much lower risk of post inflammatory hyperpigmentation. We understand that our study is limited by the small patient population and limited follow up period. We look forward to the results of larger-scale studies to firmly establish the role of the dual wavelength picosecond laser for treatment of pigmentary conditions in patients with skin of color. 
